Redhill Biophrma ADR (RDHL) 15.05 $RDHL RedHill

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:19 PM

Redhill Biophrma ADR (RDHL) 15.05 $RDHL

RedHill Biopharma to Present at the 9th Annual BioPharm America International Partnering Conference
GlobeNewswire - Thu Sep 01, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will be presenting at the 9 Annual BioPharm America International Partnering Conference, on Wednesday, September 14, 2016, at 3:00 pm EDT, at the Boston Marriott Copley Place in Boston, MA.
RDHL: 15.05 (+0.17)

RedHill Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview at the Rodman & Renshaw 18 Annual Global Investment Conference, on Monday, September 12, 2016, at 3:00 pm EDT, at The Lotte New York Palace Hotel in New York.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 29, 7:00AM CDT
- RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted
RDHL: 15.05 (+0.17)

RedHill Biopharma Provides 2016 Semi-Annual R&D Update
Globe Newswire - Thu Aug 11, 8:01AM CDT
TEL-AVIV, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on select research and development potential milestones and estimated timelines.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis
Globe Newswire - Mon Aug 01, 7:07AM CDT
- The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 15.05 (+0.17)

Global Gastritis Pipeline Report 2016 - Therapeutics Review of BCWorld Pharm, Daewon Pharm, Recce Limited & RedHill Biopharma Ltd. - Research and Markets
BusinessWire - Fri Jun 24, 5:59AM CDT
Research and Markets has announced the addition of the "Gastritis - Pipeline Review, H1 2016" report to their offering.
RDHL: 15.05 (+0.17)

RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 15.05 (+0.17), ANIP: 59.49 (-1.93), PFE: 34.67 (-0.01), BMY: 56.27 (-0.49)

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
Globe Newswire - Wed Jun 22, 7:00AM CDT
- The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially leading to a new and effective treatment for Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis (MAP) infection
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
Globe Newswire - Tue Jun 21, 8:31AM CDT
- Final results from the Phase I study with YELIVA(TM) (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
GlobeNewswire - Mon Jun 20, 7:00AM CDT
-- The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S.
RDHL: 15.05 (+0.17)

RedHill Biopharma to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY.
RDHL: 15.05 (+0.17)

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 15.05 (+0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navimow Powers TOP 14 with Tech: A Winning Play

A Technological Leap for French Rugby Innovation and precision in partnerships—those words don't usually pop up together when chatting about a rugby league. But here we are, discussing the TOP 14, the elite French rugby championship, pairing up with Segway Navimow. This brand, under the umbrella of Ninebot Limited (689009.SH), is stepping into the world of sports for...

Tech Breakthroughs in Cancer and Space Energy Aired

Science and Technology at the Forefront Saturday nights usually have folks kicking back with some reality shows or maybe cheering on their favorite sports team. But this September 12, savvy viewers have a chance to dive deep into the guts of cutting-edge science and tech on Bloomberg Television. We're talking about 'Advancements with Ted Danson'—where science isn’t...

Consumer365 Highlights Happy Head's Personalized Hair Solutions

Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...

Huion Kamvas Pad 12: A Creative Power Tool

The Kamvas Pad 12 Hits the Market In a crowded tablet market that's fierce with innovation, Huion tossed their latest tool into the ring—the Kamvas Pad 12. Now, anyone who’s been watching the digital art scene won't be surprised that Huion, with its decade and a half of digital prowess, is pulling another tablet trick out of its hat. Key Features and Innovations If...

Hyosung Targets U.S. AI Power Market with Advanced SST

Hyosung's Game-Changing Move in the AI Power Sector Guess what? The AI era's heating up, and it's dragging the power sector along for a wild ride. Hyosung Chairman Hyun-Joon Cho peered into that future and decided it's all-in time for the U.S. power market. With AI and data centers cranking up power demands like never before, those rickety old wires need an upgrade fast....

Sony Expands Versatile Wireless Headphone Lineup: 2026

Renewed Focus on Sound: Sony's Latest Headphones Sony's dipping into the headphone market this time with a splash of style and sound signature updates. We've got the WH-1000XM4C, a next-gen version of the top-dog noise-cancelling cans, that are gonna catch the eye of every audiophile and traveler out there. WH-1000XM4C: The Flagship gets a Lift What they're offering is...

Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Nuix Leverages AI for Transformative Legal Review

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Papa John's Faces Investor Lawsuit: Class Action Looms

Papa John's in Hot Water Again? Look, just when you think the pizza game is all dough and cheesy goodness, along comes a legal scuffle to toss our assumptions. Bronstein, Gewirtz & Grossman, LLC has slapped a class action lawsuit against Papa John's International, Inc. (NASDAQ: PZZA), claiming the company and some of its higher-ups haven't been playing fair with the...

XiamenAir Takes Off with Fujian-London Link

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...